A pair of promising preclinical nucleoside polymerase inhibitors for hepatitis C might be the driving force behind J&J’s $1.75 billion buyout of Alios, even though the privately held biotech’s most advanced candidate, ALS-8176, in Phase II for respiratory syncytial virus, also is a fit for J&J’s anti-infective strategy.
Johnson & Johnson sees Alios BioPharma Inc. as a perfect fit for advancing its anti-infective drug-development strategy, with a Phase II candidate for respiratory syncytial virus and a pair of preclinical hepatitis C compounds that bolster the commercial viability of the pharma’s hepatitis C blockbuster Olysio (simeprevir).
The twin primary areas of focus for Janssen Pharmaceutical Cos.’s drug development strategy in infectious diseases are respiratory infection...
The suits are an early test of the Arkansas law banning company ownership of PBMs and pharmacies in the state, as other states consider similar legislation.
An unintended consequence of a provision framed as an administrative change in the bill could significantly reduce medication adherence among low-income older adults and increase mortality, a study found.
The whole contract research organization industry is being impacted by the current volatility in the pharmaceutical industry.
HHS Secretary Kennedy's new ACIP appointments include multiple members of anti-vaccine groups and people who have spread misinformation about COVID-19 vaccines.
Commissioner Martin Makary told staff that plans are being developed to centralize HR, IT, travel and other functions, which were heavily impacted by the 1 April reduction-in-force.
The House Appropriations Committee wants an analysis of how issues that led to CRLs could have been resolved within the first review cycle and seeks an agency crackdown on counterfeit GLP-1 agonists.
While the adoption of most favored nation drug pricing in the US stands to affect Japanese biopharma firms now heavily reliant on this market, it might also present an opportunity for pricing and policy reforms at home.
